Live tape
Top 8, mentions 7d11,446SPCX2,425 mentions▲ +0.08GOOGL1,984 mentions▲ +0.02META1,790 mentions▲ +0.04TSLA1,703 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ886 mentions▲ +0.05AMZN843 mentions▲ +0.06NVDA842 mentions▲ +0.06

Equity · Healthcare

AGMB

NASDAQ

Agomab Therapeutics NV (AGMB)

$9.05 −2.32% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026
Price · Chart
63 sessions
$16 $8 28 Jul 23 Oct

The line runs $12.46 on 28 July through $9.05 on 23 October, on a scale from $8 to $16. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 28 Jul – 23 Oct 2026
52-week range $8.18 – $17.73
Avg volume 6.4K

as of Oct 23, 2026

Agomab Therapeutics NV (AGMB) insider trades

SEC Form 4 · last 90 days · newest reported trade 21 Oct 2026

In the 90 days to 26 Oct 2026, Agomab Therapeutics NV insiders reported 7 open-market purchases and no sales (SEC Form 4).

Open-market buys 7
Open-market sells 0
Net bought $400K
Non-trade filings 0
Date Insider Type Shares Value
21 Oct 2026 Epstein David R Director Buy 10,000 $89K
08 Oct 2026 Epstein David R Director Buy 5,000 $45K
06 Oct 2026 Knotnerus Tim Jasper Chief Executive Officer Buy 5,000 $44K
06 Oct 2026 Kemula Pierre Thadee Victor Chief Financial Officer Buy 10,000 $86K
06 Oct 2026 Epstein David R Director Buy 5,000 $44K
05 Oct 2026 Knotnerus Tim Jasper Chief Executive Officer Buy 6,000 $51K
05 Oct 2026 Epstein David R Director Buy 5,000 $43K

Agomab Therapeutics NV (AGMB) institutional holders (13F)

SEC Form 13F SEC EDGAR

1 of the 45 institutional funds we track reported a Agomab Therapeutics NV position for the quarter ended 30 Jun 2026 — a combined $235K; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Added +26.9% shares 18,072 $235K
Citadel Advisors Exited
D. E. Shaw & Co. Exited
Millennium Management Exited

Agomab Therapeutics NV (AGMB) fails-to-deliver

SEC CNS data SEC

On 23 Sep 2026, 1,074 shares of Agomab Therapeutics NV failed to deliver (about $12K) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
23 Sep 2026 1,074 $12K 0.003%
22 Sep 2026 2,057 $24K 0.006%
21 Sep 2026 3,451 $42K 0.010%
17 Sep 2026 1,829 $21K 0.005%

Agomab Therapeutics NV (AGMB): frequently asked questions

From live data

Have Agomab Therapeutics NV insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, Agomab Therapeutics NV insiders reported 7 open-market purchases and no sales (SEC Form 4).

How many institutions hold Agomab Therapeutics NV?

1 of the 45 institutional funds we track reported a Agomab Therapeutics NV position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Agomab Therapeutics NV had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Agomab Therapeutics NV is dated 23 Sep 2026, when 1,074 shares failed to deliver.

What exchange is Agomab Therapeutics NV listed on?

Agomab Therapeutics NV trades on NASDAQ under the ticker AGMB.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR 13F filings
  4. SECSEC fails-to-deliver (CNS) data